Objective
This research aims to evaluate the preclinical meritorious and anticancer effects of Metformin in a Xenograft model of breast cancer.
Methods
This interventional trial was conducted during a defined period of 5 months (August 2016 January 2017). We used a Xenograft model of nude BALB/c mice. A sample size of 50 mice, allocated into two groups and designated as Group A and Group B for Metformin and negative control groups, respectively. The anticancer activity of Metformin has been evaluated by comparing the tumour volume, tumour weight, tumour regression ratio, percentage regression, and survival rate.
Results
Compared with the control group, Metformin can significantly reduce the progression of tumour in the Xenograft model of breast cancer induced by MCF-7. This is reflected by significant differences in tumour volume at the final follow-up (
p =
<0.001). Our findings are further supported by a significant reduction of the tumour growth rate (
p
= <0.001) and tumour weight (
p =
<0.001) in the Metformin group than in the control group. Similarly, the total survival rate and tumour regression are more significantly correlated in the Metformin group.
Conclusion
This study demonstrates that Metformin can significantly reduce the tumour growth and can increase the survival rate in a Xenograft model of breast cancer.
Aim: To look at anti-cancer effects of a variety of novel drugs on a variety of cancerous cell lines in the quest for a more inexpensive and effective anti-cancer treatment. Methodology: The research was carried out in conjunction with PCMD at JPMC's BMSI Department of Pharmacology. The experiment lasted about eight months (from April to November 2016). Noninvasive estrogen-dependent tumours, invasive estrogen-independent breast cancer, colorectal cancer, and cervical cancer were all depicted using MCF-7, HT-29, MDA-MB-231and HeLa cell lines, in that order. The MTT assay was used to improve the drugs' anticancer or antiproliferative efficacy in vitro. Using the MTT test, we determined the vitality of all treated tumour cell lines as well as the IC50 values of each chemical against all malignant cell lines. Results: This study demonstrated thatMetformin significantly decreased the survivability of MCF7, HT-29, MDA-MB-231, and Hela cell lines when compared to Apricoxib and Mebendazole. As a result, comparing the IC50 values of the studied agents for each of the evaluated treated cells backed up this claim. Hence, for Hela(p=0.386), MCF-7 (p=0.083), and MDA-MB-231 (p=0.083) cell lines but pochoc analysis revealed no significant differences in IC50 values of Metformin and Methotrexate. Conclusion: When compared to Apricoxib and Mebendazole, Metformin has a significant effect on the survivability of the cell lines studied. Metformin, as a result, would have been a wonderful chemotherapeutic addition Keywords: Cell lines, In vitro, MCF-7, Hela, MDA-MB-231
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.